Antiangiogenic Approaches to Age-Related Macular Degeneration in the Future

Ophthalmology

Volumn 116, Issue 10 SUPPL., 2009, Pages

  Do, Diana V ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; COMPLEMENT FACTOR H; DEXAMETHASONE; E 10030; PEGAPTANIB; PLATELET DERIVED GROWTH FACTOR INHIBITOR; RANIBIZUMAB; STRONTIUM 90; UNCLASSIFIED DRUG; VASCULOTROPIN; VERTEPORFIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; COMPLEMENT FACTOR H; FORECASTING; HUMANS; MACULAR DEGENERATION; PLATELET-DERIVED GROWTH FACTOR; RADIOTHERAPY;

EID: 70349469697     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.06.049     Document Type: Article

References (14)

1. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119 (2001) 1417-1436
2. Friedman D.S., O'Colmain B.J., Munoz B., et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122 (2004) 564-572
3. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
4. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
5. Barouch F.C., and Miller J.W. Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration. Int Ophthalmol Clin 44 (2004) 23-32
6. Nguyen Q.D., Shah S.M., Hafiz G., et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113 (2006) 1522e1-1522e14
7. ClinicalTrials.gov. A phase 1, safety, tolerability and pharmacokinetic profile of intravitreous injections of E10030 (anti-PDGF pegylated aptamer) in subjects with neovascular age-related macular degeneration. http://www.clinicaltrials.gov/ct2/show/NCT00569140?term=nct00569140&rank=1 Accessed August 14, 2009
8. Edwards A.O., Ritter III R., Abel K.J., et al. Complement factor H polymorphism and age-related macular degeneration. Science 308 (2005) 421-424
9. Scholl H.P., Fleckenstein M., Charbel I.P., et al. An update on the genetics of age-related macular degeneration. Mol Vis 13 (2007) 196-205
10. Gehrs K.M., Anderson D.H., Johnson L.V., and Hageman G.S. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med 38 (2006) 450-471
11. Brantley Jr. M.A., Fang A.M., King J.M., et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114 (2007) 2168-2173
12. Spaide R.F. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 141 (2006) 149-156
13. ClinicalTrials.gov. Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone in Combination for AMD Lesions (RADICAL). http://www.clinicaltrials.gov/ct2/show/NCT00492284?term=RADICAL+AMD+Lesions&rank=1 Accessed January 19, 2009
14. ClinicalTrials.gov. Efficacy/safety of verteporfin photodynamic therapy and ranibizumab compared with ranibizumab in patients with subfoveal choroidal neovascularization. http://www.clinicaltrials.gov/ct2/show/NCT00436553?term=verteporfin&spons=%22Novartis%22&spons_ex=Y&rank=3 Accessed January 19, 2009